Regeneron Pharmaceuticals News

The analysts wrote, "We increased our probability of approval for Regeneron's anti-PCSK9 antibody from 30% to 50% due to highly favorable phase 2 data , recently concluded end-of-phase 2 meetings with both the FDA and EMA, and a global phase 3 program that will start in coming weeks.

Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of /REGN727 is a subcutaneously administered, fully-human antibody targeting PCSK9 in clinical development.

With full results reported in heterozygous familial hypercholesterolemia for its experimental PCSK9 antibody, Sanofi and partner Regeneron Pharmaceuticals have now completed a triumvirate of positive phase II data for REGN727 , which will go some way to validating this novel approach for lowering 'bad cholesterol'. Large pivotal trials are now ... (more)

Elizabeth Terlizzi and Bernard Terlizzi , both of Hopewell Junction, N.Y., announce the engagement of their daughter, Christina Terlizzi, to Alexander Adler, son of Stephen Adler of Bergenfield, N.J., and the late Sheryl Adler .

Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 is a subcutaneously administered, fully-human antibody targeting PCSK9 in clinical development.

Editor's Note: the following is a copy of theA Bellas Restaurant Award Presentation made on behalf of the Chamber at the monthly Chamber meeting this past Thursday, May 17th, at Regeneron: For 33 years Bellas Restaurant has served as the anchor of the Tarrytown community.

New York Biotechnology Association , the voice of New York State's bioscience industry, today announced that the 2012 honorees of the Association's annual leadership awards will be the leaders of Regeneron Pharmaceuticals, New York's largest biotechnology company: Dr.

Very few sectors have been able to avoid the sell-off in May. The strongest of the group has been the biotech stocks, which measured by the Dow Jones Biotechnology Index, is at an all-time high.

Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs.

's stock had its "buy" rating restated by analysts at Jefferies Group in a research report issued to clients and investors on Wednesday.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.

U.S. drug advisers unanimously voted against Regeneron Pharmaceuticals Inc's experimental drug to prevent gout flares, based on studies that tested the drug for only 16 weeks.

Regeneron Pharmaceuticals Inc. failed to win the backing of advisers to the U.S. Food and Drug Administration to expand the use of the autoinflammatory drug Arcalyst to include patients undergoing gout treatments.

TARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd.

We present here two noteworthy insider buys and eight noteworthy insider sells in the healthcare sector from Wednesday through Friday's over 1,100 separate SEC Form 4 filings, as part of our daily and weekly coverage of insider trades .

The Food and Drug Administration staff on Friday said the injectable drug, called Arcalyst, was meant to be used for only 16 weeks to prevent gout flares - the first treatment for the condition with such a limited timeline.

The early success of Regeneron's eye drug Eylea overshadowed the company's recent movement toward winning approval for a gout treatment.

Staff walk among the new buildings at the the U.S. Food and Drug Administration headquarters in Silver Spring, Maryland, November 5, 2009.

's stock had its "neutral" rating reaffirmed by Zacks in a research note issued on Monday.